John Liddell

Chief Technologist • CPI

Dr John Liddell is a Chief Technologist at CPI Biologics based in Darlington, UK. The CPI is a Research and Technology Organisation and is part of the UK Catapult network. CPI Biologics supports UK activities in advanced bioprocessing covering a wide range of advanced therapy products including viral vectors, RNA/LNP products, and exosomes, as well as biopharmaceutical products such as antibodies, non-antibody proteins, VLPs and vaccines. He provides support to biopharmaceutical development to increase access to new therapies through the application of innovative technologies.

Prior to CPI, John’s previous experience involved the development and manufacture of biotherapeutics, working in senior process development roles with global organisations, including Fujifilm Diosynth Biotechnologies, Merck &Co, Avecia Biologics, Zeneca and ICI.

He has almost 30 years of experience in bioprocessing with experience encompassing all phases of bioprocess development from early phase process definition to late phase process validation and commercial production

Also speaking

Sofia Hakansson Buch

Vice President for Cell Therapy CMC • Novo Nordisk

Stuart Curbishley

Head of Business and Project Development – Advanced Therapies • University of Birmingham

Francesca Kinsella

Consultant Haematologist (Stem Cell Transplantation) • University of Birmingham

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.